Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 260

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs

Open access
Miura, Koh, Kinouchi, Makoto, Ishida, Kazuyuki, Fujibuchi, Wataru, Naitoh, Takeshi, Ogawa, Hitoshi, Ando, Toshinori, Yazaki, Nobuki, Watanabe, Kazuhiro, Haneda, Sho, Shibata, Chikashi, Sasaki, Iwao·2010·Cancers

Abstract

5-Fluorouracil (5-FU) is a key anticancer drug that for its broad antitumor activity, as well as for its synergism with other anticancer drugs, has been used to treat various types of malignancies. In chemotherapeutic regimens, 5-FU has been combined with oxaliplatin, irinotecan and other drugs as a continuous intravenous infusion. Recent clinical chemotherapy studies have shown that several of the regimens with oral 5-FU drugs are not inferior compared to those involving continuous 5-FU infusion chemotherapy, and it is probable that in some regimens continuous 5-FU infusion can be replaced by oral 5-FU drugs. Historically, both the pharmaceutical industry and academia in Japan have been involved in the development of oral 5-FU drugs, and this review will focus on the current knowledge of 5-FU anabolism and catabolism, and the available information about the various orally-administrable 5-FU drugs, including UFT, S-1 and capecitabine. Clinical studies comparing the efficacy and adverse events of S-1 and capecitabine have been reported, and the accumulated results should be utilized to optimize the treatment of cancer patients. On the other hand, it is essential to elucidate the pharmacokinetic mechanism of each of the newly-developed drugs, to correctly select the drugs for each patient in the clinical setting, and to further develop optimized drug derivatives.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers2031717

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 260

Metadata

Authors
Miura, K., Kinouchi, M., Ishida, K., Fujibuchi, W., Naitoh, T., Ogawa, H., Ando, T., Yazaki, N., Watanabe, K., Haneda, S., Shibata, C., & Sasaki, I.
Venue
Cancers
Publisher
MDPI AG
Published
2010-09-17
Volume
2
Issue
3
Pages
1717-1730
ISSN
2072-6694 (ISSN-L)
OpenAlex
W2103846273
Cited by
260
References
44
FWCI
0.57
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs. https://app.cochat.ai/papers/10.3390/cancers2031717
The paper
Miura, K., Kinouchi, M., Ishida, K., Fujibuchi, W., Naitoh, T., Ogawa, H., Ando, T., Yazaki, N., Watanabe, K., Haneda, S., Shibata, C., & Sasaki, I. (2010). 5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs. Cancers. https://doi.org/10.3390/cancers2031717

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.